Infrared-monitored cold response in the assessment of Raynaud's phenomenon

Clinical and Experimental Dermatology

Volumn 31, Issue 1, 2006, Pages 6-12

  Foerster, J ^a   Wittstock, S ^a   Fleischanderl, S ^a   Storch, A ^a   Riemekasten, G ^a   Hochmuth, O ^b   Meffert, B ^b   Meffert, H ^a   Worm, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD FLOW; BODY TEMPERATURE; COHORT ANALYSIS; COLD; FINGER; HOSPITALIZATION; HUMAN; INFRARED RADIATION; INSTRUMENTATION; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLETHYSMOGRAPHY; PREDICTION AND FORECASTING; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; THERMOGRAPHY;

BODY TEMPERATURE; COHORT STUDIES; COLD; FINGERS; HUMANS; INFRARED RAYS; PLETHYSMOGRAPHY; PREDICTIVE VALUE OF TESTS; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; THERMOGRAPHY;

EID: 33646093032     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01995.x     Document Type: Article

References (27)

1. Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyn-dromes. J Rheumatol 1996; 23: 1917-20.
2. Kingma K, Wollersheim H, Thien T. Double-blind, placebo-controlled study of intravenous prostacyclin on hemody-namics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. J Cardiovasc Pharmacol 1995; 26: 388-93.
3. Thompson AE, Shea B, Welch V et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 1841-7.
4. Dziadzio M, Denton CP, Smith R et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42: 2646-55.
5. Hirschl M, Katzenschlager R, Ammer K et al. Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon. Vasa 2002; 31: 91-4.
6. al-Awami M, Schillinger M, Gschwandtner ME et al. Low level laser treatment of primary and secondary Raynaud's phenomenon. Vasa 2001; 30: 281-4.
7. Casale R, Generini S, Luppi F et al. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Ray-naud's phenomenon) in a case of early systemic sclerosis. Arthritis Rheum 2004; 51: 665-9.
8. Clark S, Dunn G, Moore T et al. Comparison of thermo-graphy and laser Doppler imaging in the assessment of Raynaud's phenomenon. Microvasc Res 2003; 66: 73-6.
9. von Bierbrauer A, Schilk I, Lucke C et al. Infrared ther-mography in the diagnosis of Raynaud's phenomenon in vibration-induced white finger. Vasa 1998; 27: 94-9.
10. Pistorius MA, Planchon B, de Faucal P. Plethysmographic cold test for diagnosis and evaluation of the severity of Raynaud's phenomenon. Validation of the method by factorial analysis of correspondences in 541 patients. Int Angiol 1994; 13: 10-14.
11. Smyth AE, Bell AL, Bruce IN et al. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 2000; 59: 870-4.
12. Kanetaka T, Komiyama T, Onozuka A et al. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon. Eur J Vasc Endovasc Surg 2004; 27: 414-16.
13. Meffert H, Sönnichsen N, Meffert B. Skin-rewarming curves. Lancet 1972; 7780: 769-70.
14. Rietschel L, Meffert H, Sonnichsen N. [Measurement of skin temperature with the infra-red radiation measuring device by Kortum]. Dermatol Monatsschr 1969; 155: 802-12.
15. Meffert H, Sonnichsen N. [Rewarming, heat conduction ability and blood circulation of the skin in healthy subjects and scleroderma patients]. Dermatol Monatsschr 1974; 160: 282-90.
16. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984-91.
17. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410-20.
18. Lindberg LG, Oberg PA. Photoplethysmography: Part 2: Influence of light source wavelength. Med Biol Eng Comput 1991; 29: 48-54.
19. Grassi W, De Angelis R, Lapadula G et al. Clinical diagnosis found in patients with Raynaud's phenomenon: a multi-centre study. Rheumatol Int 1998; 18: 17-20.
20. Darton K, Black CM. Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon. Br J Rheumatol 1991; 30: 190-5.
21. Sambo P, Amico D, Giacomelli R et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001; 28: 2257-62.
22. Schuhfried O, Vacariu G, Lang T et al. Thermographic parameters in the diagnosis of secondary Raynaud's phenomenon. Arch Phys Med Rehabil 2000; 81: 495-9.
23. al-Awami M, Schillinger M, Maca T et al. Low level laser therapy for treatment of primary and secondary Raynaud's phenomenon. Vasa 2004; 33: 25-9.
24. O'Reilly D, Taylor L, el-Hadidy K et al. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. Ann Rheum Dis 1992; 51: 1193-6.
25. Meffert H, Rietschel L, Bauerhorst V et al. [Comparative infrared determinations of the rewarming of the skin in endogenous and atopic eczema]. Dermatol Monatsschr 1971; 157: 108-14.
26. Wise RA, Wigley FM, White B et al. Efficacy and tolerability of a selective alpha (2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004; 50: 3994-4001.
27. Valentini G, Bencivelli W, Bombardieri S et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003; 62: 901-3.